Results 91 to 100 of about 804,384 (336)

EWING TUMOR: DIFFERENTIAL DIAGNOSIS AND BASIS FOR ONCOLOGICAL AND SURGICAL TREATMENT [PDF]

Coluna/Columna
Ewing sarcoma (ES) is a highly aggressive primary bone tumor that poses significant diagnostic and therapeutic challenges when affecting the spinal column.
Debora Yumi Yoshimura Orlandin Alves, Italo Gerardo Rotondo, Matheus Trindade Bruxelas de Freitas, Douglas Kenji Narazaki   +3 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. [PDF]

, 1991
In the initial series of 198 patients treated at the National Cancer Institute (NCI) with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy for Hodgkin's disease, a review of presenting chest radiographs available on 192 of ...
V T DeVita, E Glatstein, P L Duffey, R C Young, J B Hill, A Russo, D L Longo, E S Jaffe, S M Hubbard   +8 more
core   +1 more source

Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data

Signal Transduction and Targeted Therapy
The sole use of single modality data often fails to capture the complex heterogeneity among patients, including the variability in resistance to anti-HER2 therapy and outcomes of combined treatment regimens, for the treatment of HER2-positive gastric ...
Zi Chen, Yang Chen, Yu Sun, Lei Tang, Li Zhang, Yajie Hu, M. He, Zhiwei Li, Siyuan Cheng, Jiajia Yuan, Zhenghang Wang, Yakun Wang, Jie Zhao, J. Gong, Li-ying Zhao, B. Cao, Guoxin Li, Xiaotian Zhang, Bin Dong, Lin Shen   +19 more
semanticscholar   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. [PDF]

, 2010
Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely
Clarkson, Jan E.; id_orcid, null The CSROC Expert Panel, Furness, Susan, Glenny, A.M., Oliver, R., Jan E Clarkson, Macluskey, Michaelina; id_orcid, Furness, S, Glenny, Anne-Marie, Macluskey, M., Clarkson, Jan E., The CSROC Expert Panel, CSROC Expert Panel, Chan, Kelvin K.W., Chan, K.K.W., Conway, DI, Clarkson, Jan E, Conway, David I., Glenny, AM, Clarkson, JE, Kelvin KW Chan, Pavitt, S., Worthington, Helen V, CSROC Expert Panel, [Unknown], Michaelina Macluskey, Furness, S., Worthington, Helen V., The CSROC Expert Panel,, Chan, Kelvin K. W., Pavitt, S, Chan, Kelvin KW, Anne-Marie Glenny, Oliver, R, Glenny, Anne Marie; id_orcid, David I Conway, Conway, D.I., Macluskey, Michaelina, Worthington, HV; id_orcid, Clarkson, J.E., Pavitt, Sue, Chan, KK, Worthington, HV, Macluskey, M, Worthington, Helen V.; id_orcid, Richard Oliver, Oliver, Richard, Helen V Worthington, Susan Furness, Sue Pavitt, Paul Brocklehurst, Worthington, H.V., Brocklehurst, Paul, Brocklehurst, P   +52 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

The influence of patient-related constutional and environmental factors on early results of a combined modality therapy of esophageal cancer [PDF]

, 2016
Among many various factors affecting the outcome of cancer treatment one can distinguish patient, tumor- and treatment-related factors. The association of patient-related factors and results of a combined modality therapy of esophageal cancer has not ...
Pudło, Kamil, Lampe, Paweł, Dąbrowski, Andrzej, Skoczylas, Tomasz, Szawłowski, Andrzej, Wallner, Grzegorz, Błotniak, Alan, Kozłowski, Mirosław   +7 more
core  

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study

Frontiers in Immunology
ObjectivesThis study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab biosimilar as first-line therapy for intermediate-advanced hepatocellular carcinoma (HCC).Materials and methodsA ...
Li-Wei Deng, Jun-Feng Liu, Hai-Yan Yu, Bo Peng, Bin Liu, Shi-Feng Feng, Dong-Xu Liu, Yan-Yuan Sun, Yan Chen, Jian-Jian Chen, Chi Zhang, Hai-Qing Wang, Guo-Hui Xu, Le Liu, Guo Wei, Yi Ren, Lei Cao, Yong Zhao, Xue-Gang Yang   +18 more
doaj   +1 more source